The Genomic Profile of Pregnancy-Associated Breast Cancer: A Systematic Review.

Autor:	Korakiti AM; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Moutafi M; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Zografos E; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Dimopoulos MA; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Zagouri F; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2020 Sep 11; Vol. 10, pp. 1773. Date of Electronic Publication: 2020 Sep 11 (Print Publication: 2020).
DOI:	10.3389/fonc.2020.01773
Abstrakt:	Breast cancer is the most common malignancy diagnosed during pregnancy. Strong data on the genomic profile of pregnancy-associated breast cancer are lacking. This systematic review aims to integrate and analyze all existing data from the literature regarding the genomic background and the gene mutational patterns of pregnancy-associated breast cancer. Using various genomic analysis methods, multiple differentially expressed genes and numerous non-silent mutations have been detected. More particularly, our review demonstrates the aberrant expression of several oncogenes (e.g., MYC, SRC, FOS ), tumor suppressor genes (e.g., TP53, PTEN, CAV1 ), apoptosis regulators (e.g., PDCD4, BCL2, BIRC5 ), transcription regulators (e.g., JUN, KLF1, SP110 ), genes involved in DNA repair mechanisms (e.g., Sig20, BRCA1, BRCA2, FEN1 ), in cell proliferation (e.g., AURKA, MKI67 ), in the immune response (e.g., PD1, PDL1 ), and in other significant biological processes (e.g., protein modification, internal cell motility). Further research on the genomic profile of pregnancy-associated breast cancer is urgently required in order to identify potential biomarkers facilitating early-stage diagnosis and individualized therapy. (Copyright © 2020 Korakiti, Moutafi, Zografos, Dimopoulos and Zagouri.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu